List of Excipients in Branded Drug DEFERASOROX

« Back to Dashboard

Generic Drugs Containing DEFERASOROX

Company	Ingredient	NDC	Excipient
MSN LABORATORIES PRIVATE LIMITED	deferasirox	69539-200	CASTOR OIL
MSN LABORATORIES PRIVATE LIMITED	deferasirox	69539-200	CELLULOSE, MICROCRYSTALLINE
MSN LABORATORIES PRIVATE LIMITED	deferasirox	69539-200	CROSCARMELLOSE SODIUM
MSN LABORATORIES PRIVATE LIMITED	deferasirox	69539-200	HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
MSN LABORATORIES PRIVATE LIMITED	deferasirox	69539-200	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in DEFERASOROX?

# Of NDCs	Excipient
2	CASTOR OIL
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
2	LACTOSE MONOHYDRATE

Deferasirox Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Deferasirox has two established oral product platforms: the legacy dispersible tablet marketed as Exjade and the film-coated tablet marketed as Jadenu. The commercial opportunity is concentrated in improved pediatric acceptability, lower-cost generic manufacturing, flexible dosing, and differentiated formulations that address food effects, dispersion, swallowing, and adherence. Because deferasirox is a small molecule, biosimilar competition is not relevant; abbreviated new drug applications, formulation patents, manufacturing know-how, and regulatory equivalence are the principal competitive factors.

What products and dosage forms contain deferasirox?

Deferasirox is an oral iron chelator used to treat chronic iron overload caused by blood transfusions and, in selected patients, non-transfusion-dependent thalassemia. The FDA-approved product architecture includes two materially different dosage forms.

Product	Dosage form	Strengths	Main administration characteristic	Commercial role
Exjade	Tablet for oral suspension	125, 250, 500 mg	Must be dispersed in liquid before administration	Legacy product; technically more complex for patients and caregivers
Jadenu	Film-coated tablet	90, 180, 360 mg	Swallowed whole or dispersed in soft food or liquid under label instructions	Current reference formulation for simplified administration
Generic deferasirox	Tablets for oral suspension and film-coated tablets	Varies by ANDA	Depends on approved dosage form	Price competition and pharmacy substitution

Exjade received FDA approval in 2005. Jadenu was approved in 2015 as a newer oral presentation intended to improve administration and dosing convenience (FDA, 2005; FDA, 2015).

What excipients are used in Exjade and Jadenu?

The main excipient strategy uses standard direct-compression and tablet-disintegration materials rather than novel delivery technology.

Exjade excipient platform

Exjade dispersible tablets contain excipients associated with rapid wetting, dispersion, powder binding, and tablet strength. The FDA labeling identifies materials including:

• Microcrystalline cellulose
• Crospovidone
• Povidone
• Sodium lauryl sulfate
• Lactose monohydrate
• Colloidal silicon dioxide
• Talc
• Magnesium stearate

The formulation has a functional requirement that is absent from a conventional swallowed tablet: the tablet must disperse in liquid before administration. Crospovidone supports rapid breakup, while sodium lauryl sulfate can improve wetting of the active pharmaceutical ingredient. Povidone contributes binding and powder-process performance. Lactose and microcrystalline cellulose provide bulk and compressibility.

The commercial disadvantage is operational. Patients must prepare the dose in water or another permitted liquid and consume it promptly. Residue remaining in the cup can create dose-delivery variability and reduce adherence.

Jadenu excipient platform

Jadenu film-coated tablets use a more conventional solid oral formulation. The inactive ingredients listed in FDA labeling include:

• Microcrystalline cellulose
• Crospovidone
• Povidone
• Sodium lauryl sulfate
• Colloidal silicon dioxide
• Magnesium stearate
• Film-coating materials, including hypromellose, talc, titanium dioxide, and colorants that vary by strength

The core retains the wetting and disintegration functions used in Exjade, but the finished product eliminates the required pre-dispersion step. The film coat supports tablet identification, handling, swallowability, and protection of the compressed core.

Jadenu has higher relative bioavailability than Exjade. Its label therefore uses lower nominal daily doses than the corresponding Exjade regimen. Dose conversion is a clinical and regulatory issue, not simply a tablet-strength substitution (FDA, 2015).

How does the Jadenu formulation compare with Exjade?

Jadenu’s principal commercial advantage is dosage-form simplification.

Attribute	Exjade	Jadenu
Administration	Disperse before dosing	Swallow or use permitted dispersion method
Patient burden	Higher	Lower
Relative exposure	Lower	Higher
Dose conversion	Baseline reference for older regimen	Requires lower dose than Exjade
Excipient complexity	Dispersion-focused	Compression and film-coating focused
Pediatric usability	Acceptability depends on liquid preparation	Improved, but tablet size and swallowing remain constraints
Generic development	Oral-suspension performance is critical	Tablet bioequivalence and food-effect performance are critical

Jadenu also has food-related administration requirements. The label permits administration on an empty stomach or with a light meal, but high-fat meals can alter exposure. A generic or reformulated product must therefore control not only conventional bioequivalence but also dissolution, particle size, food effect, and dose proportionality across strengths.

What excipient functions are commercially important for deferasirox?

Wetting and dissolution

Deferasirox has limited aqueous solubility, making wetting agents and particle engineering commercially relevant. Sodium lauryl sulfate is used in the reference products to improve contact between the active ingredient and aqueous media. Alternative surfactants could create an opportunity if they improve dissolution without increasing gastrointestinal intolerance or complicating regulatory equivalence.

Candidate approaches include:

• Controlled particle-size API
• Spray-dried or co-precipitated API
• Amorphous solid dispersion
• Alternative surfactant systems
• Co-milled API-excipient blends
• Improved tablet porosity and liquid penetration

The primary development risk is that a dissolution improvement may increase systemic exposure beyond the reference product’s profile.

Disintegration and dispersion

For Exjade-type products, the excipient system must produce rapid and complete dispersion. A product that disperses slowly, forms floating agglomerates, or leaves substantial residue creates a practical dose-delivery problem.

Commercially relevant variables include:

• Crospovidone grade and loading
• Particle-size distribution
• Tablet porosity
• Compression force
• Wetting-agent concentration
• Dispersion time across water temperatures
• Residual material after transfer from the dosing vessel

These attributes can become critical quality attributes in an abbreviated or line-extension program.

Taste and mouthfeel

Deferasirox products are used chronically and often in pediatric populations. Bitterness, chalkiness, grittiness, and residual mouth coating can reduce adherence.

Taste-masking opportunities include:

• Polymer coating of API particles
• Ion-exchange resin complexes
• Lipid-based coating
• Flavor systems compatible with iron-chelation therapy
• Microgranules for sprinkling on soft food
• Multiparticulate dosage forms
• Sweetener and acidulant optimization

Taste masking must not materially change dissolution or exposure. A coated particle that improves palatability but delays release can create a bioequivalence problem.

Swallowability

The 360 mg Jadenu tablet is relatively high dose by mass. This creates an opportunity for smaller, higher-load tablets, mini-tablets, orally disintegrating systems, or granules.

Potential product concepts include:

Product concept	Target user	Main value proposition	Main technical barrier
Mini-tablets	Young children and patients with dysphagia	Flexible dosing and easier swallowing	Dose uniformity and packaging
Sprinkle granules	Pediatric patients	Administration with soft food	Taste masking and food interaction
Oral powder for suspension	Patients unable to swallow tablets	Flexible administration	Stability, sedimentation, and dose transfer
Orally disintegrating tablet	Patients with swallowing difficulty	No water or limited water requirement	High drug load and bitterness
Smaller high-load tablet	General population	Better swallowability	Compression, friability, and dissolution
Modified-release tablet	Patients with gastrointestinal intolerance	Potentially smoother exposure	Uncertain clinical value and higher regulatory burden

A liquid or sprinkle product has the clearest pediatric rationale, but it also has the highest risk of dose loss, settling, container retention, and microbial-control requirements.

What formulation patents could protect a deferasirox product?

The strongest new intellectual-property opportunities are unlikely to come from routine use of microcrystalline cellulose, povidone, or magnesium stearate. Those materials are widely used and generally difficult to protect broadly.

More defensible claim categories include:

1. A defined deferasirox particle-size distribution.
2. A specific amorphous or crystalline form.
3. A composition with a measured dissolution profile.
4. A taste-masked deferasirox particle or multiparticulate.
5. A low-dose pediatric granule with defined dose uniformity.
6. A formulation that maintains exposure under a specified meal condition.
7. A stable aqueous or reconstituted suspension.
8. A tablet with defined hardness, disintegration time, and dissolution behavior.
9. A co-processed excipient system that improves manufacturability.
10. A manufacturing process that controls polymorph, residual solvent, or impurity formation.

Patent strength depends on whether the claimed excipient combination produces an unexpected technical effect. A claim that merely lists common excipients at routine concentrations is vulnerable to obviousness challenges. A claim tied to a reproducible dissolution, stability, taste, or pharmacokinetic advantage is more commercially useful.

What is the FDA regulatory status of deferasirox?

Deferasirox is regulated as a small-molecule prescription drug. Generic products use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference-listed drug.

FDA regulatory issues differ by dosage form:

Tablets for oral suspension

An ANDA applicant must address:

• Dispersion time
• Uniformity after dispersion
• Residual drug in the dosing vessel
• Dissolution
• Assay and content uniformity
• Stability after manufacture
• Excipient compatibility
• Labeling for preparation and administration

Film-coated tablets

The key issues include:

• Comparative dissolution
• Pharmacokinetic bioequivalence
• Food-effect considerations
• Strength proportionality
• Tablet dimensions and scoring, where applicable
• Film-coat composition and performance
• Stability and impurity control

The FDA’s product-specific guidance and current Orange Book entries determine the precise requirements for each generic program (FDA, n.d.-a; FDA, n.d.-b).

When does deferasirox lose exclusivity and how does that affect excipient strategy?

The core commercial exclusivity associated with the original Exjade product has matured, and generic competition exists in the U.S. market. Commercial value now depends less on basic compound exclusivity and more on:

• Cost of goods
• Manufacturing yield
• Supply reliability
• Pharmacy substitution
• Dosage-form convenience
• Pediatric differentiation
• Formulation patents
• Regulatory exclusivity for a genuinely new product
• Contract manufacturing capacity

Orange Book-listed patents and exclusivity codes must be reviewed by product and dosage form. Patent coverage may differ between Exjade tablets for oral suspension and Jadenu film-coated tablets. A patent covering a method of use may not prevent approval of a generic product if the relevant use can be carved out of labeling. A formulation or composition patent can create a more direct barrier if it covers the reference product or the proposed generic’s specific formulation.

Paragraph IV risk is highest where an ANDA applicant can argue that listed patents are invalid, unenforceable, or not infringed. The risk profile is lower for a generic that uses a non-infringing excipient system, but bioequivalence constraints can narrow formulation freedom.

Which companies are challenging or competing with deferasirox?

Competition comes from several groups:

• Generic manufacturers of deferasirox tablets for oral suspension
• Generic manufacturers of deferasirox film-coated tablets
• Manufacturers of alternative iron chelators
• Specialty pharmaceutical companies pursuing pediatric or adherence-focused presentations
• Contract manufacturers with high-potency oral-solid-dose capability

The principal therapeutic alternatives are deferoxamine and deferiprone. Deferoxamine is injectable and has a substantially different administration burden. Deferiprone is an oral alternative but has a different safety-monitoring and dosing profile. Deferasirox therefore retains a commercial position based on once-daily oral administration, despite renal, hepatic, gastrointestinal, and hematologic monitoring requirements.

Because deferasirox is a small molecule, there is no biosimilar pathway. The relevant competitive terms are generic entry, authorized generics, therapeutic substitution, and differentiated reformulation.

What manufacturing and IP barriers affect deferasirox?

The molecule does not require biologic manufacturing, but commercial manufacturing still has meaningful technical barriers.

Manufacturing barriers

Key process risks include:

• API particle-size control
• Powder flow and segregation
• High drug loading
• Content uniformity across tablet strengths
• Surfactant distribution
• Compression behavior
• Film-coat uniformity
• Dissolution changes caused by scale-up
• Cleaning validation for potent active material
• Stability and impurity control

A generic manufacturer can avoid some patent risk by using a different excipient system, but the alternative formulation must still match the reference product’s exposure and dissolution characteristics.

Geographic coverage

U.S. commercial strategy depends on FDA approval, Orange Book status, state substitution rules, and payer contracting. European and other markets may use different reference products, dosage-form requirements, and pediatric obligations. A formulation patent filed only in the U.S. will not block manufacturing or sale in Europe, India, China, or other jurisdictions unless corresponding rights exist.

For multinational commercialization, applicants should separate:

• Composition-of-matter rights
• Formulation patents
• Process patents
• Use patents
• Manufacturing-site rights
• Regulatory data exclusivity
• Trademark rights
• Local reference-product requirements

What is the revenue exposure and commercial opportunity?

Revenue exposure is concentrated in chronic-use patients who require long-term iron-load management. The commercial opportunity is strongest where the formulation reduces persistent administration friction.

Opportunity	Revenue logic	Development priority
Low-cost generic film-coated tablet	High-volume pharmacy substitution	High
Pediatric sprinkle granules	Differentiated adherence and dosing	High
Taste-masked oral suspension	Addresses pediatric and dysphagia populations	High
Smaller high-load tablet	Broad patient convenience	Medium
Orally disintegrating tablet	Convenience differentiation	Medium
Novel modified-release product	Potential tolerability benefit	Low to medium
Alternative surfactant formulation	May reduce cost or improve performance	Medium

The most credible near-term opportunity is a pediatric-friendly, taste-masked multiparticulate or granule product with flexible dosing. The strongest generic opportunity is a film-coated tablet manufactured at lower cost with robust dissolution and a clean food-effect profile.

How strong is the deferasirox patent estate?

The legacy compound estate is less important than product-specific and formulation-related rights. A new entrant should evaluate the estate in four layers:

1. Orange Book-listed patents for the target reference product.
2. Unlisted formulation and process patents that may still support litigation.
3. Pending patent applications covering pediatric, taste-masked, or multiparticulate products.
4. International rights that affect API sourcing and export markets.

Common excipient systems alone generally provide limited exclusionary power. Stronger protection requires a defined composition linked to a measurable performance advantage, such as improved stability, faster dispersion, reduced food sensitivity, enhanced palatability, or controlled exposure.

What generic launch scenarios exist for deferasirox?

Three launch scenarios are commercially plausible.

Standard Paragraph IV launch

A manufacturer files an ANDA with a non-infringement or invalidity certification against listed patents. The applicant may launch after patent resolution, settlement, or expiration of the relevant stay period.

Non-Paragraph IV launch

The applicant waits for listed patents to expire or uses certifications that do not challenge remaining patent claims. This reduces litigation cost but delays entry.

Differentiated reformulation

The company develops a new dosage form or pediatric presentation through an NDA or suitable regulatory pathway. This strategy can support formulation patents and premium pricing, but it requires clinical, CMC, and commercial investment beyond a conventional ANDA.

Key Takeaways

• Exjade uses a dispersible-tablet platform; Jadenu uses a film-coated tablet platform.
• The core excipient system relies on microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, silicon dioxide, and tablet lubricants.
• The most valuable formulation opportunities involve taste masking, pediatric granules, smaller tablets, and flexible dosing.
• Deferasirox is a small molecule, so biosimilar risk does not apply.
• Generic competition is driven by ANDA approval, bioequivalence, dissolution, food-effect control, and manufacturing cost.
• Routine excipient combinations have limited patent strength.
• Stronger IP can arise from defined particle engineering, taste-masking systems, dissolution performance, stability, or pediatric dosage forms.
• The main commercial barrier is not biologic manufacturing. It is control of high drug loading, particle properties, dose uniformity, dissolution, and chronic-use tolerability.

FAQs

Can deferasirox be formulated as a liquid for pediatric patients?

Yes. A liquid or reconstituted suspension is technically feasible, but development must control sedimentation, dose uniformity, container retention, taste, chemical stability, and microbial risk.

Which excipient is most important for deferasirox dissolution?

Sodium lauryl sulfate is a key wetting agent in the reference formulations, but dissolution also depends on API particle size, tablet porosity, disintegrant performance, compression force, and surfactant distribution.

Is a deferasirox orally disintegrating tablet commercially attractive?

It could address swallowing difficulty, but the high dose and bitter taste create major formulation constraints. A multiparticulate or mini-tablet product may offer a more practical pediatric solution.

Can a generic deferasirox product use different excipients from Jadenu?

Yes. An ANDA applicant may use different inactive ingredients if the formulation meets applicable safety, pharmaceutical-equivalence, bioequivalence, dissolution, and labeling requirements.

Does deferasirox require biosimilar competition analysis?

No. Deferasirox is a chemically synthesized small molecule. Competitive analysis should focus on generic ANDAs, therapeutic alternatives, authorized generics, formulation patents, and differentiated oral dosage forms.

References

1. U.S. Food and Drug Administration. (2005). Exjade (deferasirox) prescribing information.
2. U.S. Food and Drug Administration. (2015). Jadenu (deferasirox) prescribing information.
3. U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (n.d.-b). Product-specific guidances for generic drug development.
5. DailyMed. (n.d.). Deferasirox tablets for oral suspension and deferasirox film-coated tablets: Prescribing information. National Library of Medicine.